Patents by Inventor Pascal Merchiers
Pascal Merchiers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12161717Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: June 8, 2018Date of Patent: December 10, 2024Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Patent number: 12162949Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: January 18, 2022Date of Patent: December 10, 2024Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Simone Filosto, Pascal Merchiers, Nina Eissler, Hemanta Baruah, Bianka Prinz
-
Publication number: 20240309101Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.Type: ApplicationFiled: September 20, 2023Publication date: September 19, 2024Inventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
-
Publication number: 20240141030Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: January 11, 2024Publication date: May 2, 2024Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
-
Publication number: 20240092928Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: ApplicationFiled: September 1, 2023Publication date: March 21, 2024Inventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Publication number: 20240076391Abstract: The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with a non-human primate CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.Type: ApplicationFiled: December 23, 2021Publication date: March 7, 2024Inventors: Hui Qi Lu, Catelijne Stortelers, Nadia Van Boxel, Shanna Van Zwam, Jimmy Borloo, Bruno Dombrecht, Jo Van Ginderachter, Pascal Merchiers, Rosa Martin
-
Patent number: 11919960Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in 5 pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: March 5, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Publication number: 20240052044Abstract: The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is a non-blocking binder of hCCR8.Type: ApplicationFiled: December 23, 2021Publication date: February 15, 2024Inventors: Hui Qi Lu, Catelijne Stortelers, Nadia Van Boxel, Shanna Van Zwam, Jimmy Borloo, Bruno Dombrecht, Jo Van Ginderachter, Pascal Merchiers, Rosa Martin
-
Publication number: 20240052045Abstract: The present invention relates to human CCR8 (hCCR8) binders, wherein the hCCR8 binder is cross-reactive with murine CCR8. Such binders are particularly useful for the depletion of intra-tumoural regulatory T-cells and immunotherapy in general.Type: ApplicationFiled: December 23, 2021Publication date: February 15, 2024Inventors: Hui Qi Lu, Catelijne Stortelers, Nadia Van Boxel, Shanna Van Zwam, Jimmy Borloo, Bruno Dombrecht, Jo Van Ginderachter, Pascal Merchiers, Rosa Martin
-
Patent number: 11879014Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.Type: GrantFiled: March 3, 2018Date of Patent: January 23, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Josephine Salimu, Kevin Moulder, Beatriz Goyenechea Corzo, Pascal Merchiers, Sergio Quezada, Karl Peggs, Frederick Arce Vargas, Isabelle Solomon
-
Publication number: 20240018248Abstract: The present invention relates to a combination comprising a Treg depletor and an LTBR agonist. Such a combination is particularly useful for use in the treatment of a cancer.Type: ApplicationFiled: November 30, 2021Publication date: January 18, 2024Inventors: Gabriele Bergers, Elizabeth Allen, Bruno Dombrecht, Pascal Merchiers, Jo Van Ginderachter
-
Patent number: 11873341Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: YQCVQGYRALHRGP (150 to 163) or SVCKMTHGKTRWTQP (166 to 180) on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: January 16, 2024Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11851494Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: December 26, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Sergio Quezada
-
Patent number: 11814434Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: November 14, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
-
Patent number: 11802160Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.Type: GrantFiled: February 5, 2020Date of Patent: October 31, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
-
Patent number: 11802161Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: October 31, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
-
Patent number: 11787866Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.Type: GrantFiled: February 5, 2020Date of Patent: October 17, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, Sergio Quezada, James Geoghegan, Bianka Prinz
-
Patent number: 11780930Abstract: The present disclosure provides antibodies that bind to human CD38. In particular, the antibodies and antigen-binding portions thereof are defined by particular functional characteristics. The antibodies present features compatible for manufacturing and can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.Type: GrantFiled: June 8, 2018Date of Patent: October 10, 2023Assignee: BLACK BELT THERAPEUTICS LIMITEDInventors: Pascal Merchiers, Anne Goubier, Kevin Moulder, Nina Eissler, Josephine Salimu, Simone Filosto, Beatriz Goyenechea Corzo, Hemanta Baruah, Bianka Prinz
-
Patent number: 11697688Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-674 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: QCVQGYRA and RWTQPQLICTG on CD25 Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.Type: GrantFiled: March 13, 2019Date of Patent: July 11, 2023Assignees: Tusk Therapeutics Ltd., Cancer Research Technology LimitedInventors: Anne Goubier, Beatriz Goyenechea Corzo, Josephine Salimu, Kevin Moulder, Pascal Merchiers, Mark Brown, James Geoghegan, Bianka Prinz, Sergio Quezada
-
Publication number: 20230203146Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: March 17, 2023Publication date: June 29, 2023Inventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
